Harvard Researcher David Pepin Receives KY Cha Award
The award honors new research into the hormonal mechanisms that drive ovarian aging and potential future fertility therapies.
Updated on Oct. 28, 2026 in Life Sciences

Harvard Medical School associate professor David Pepin has received the 13th KY Cha Award in Reproductive Medicine. The recognition was presented at the 82nd Scientific Congress of the American Society for Reproductive Medicine in Baltimore.
Why it matters
The award highlights emerging research into ovarian aging, a critical area for improving clinical outcomes in fertility and reproductive health. By identifying new therapeutic targets, this work addresses fundamental biological barriers to reproductive longevity.
The study, titled Extrafollicular Ovarian Steroidogenesis: Stromal Hormone Production as a Therapeutic Target in Ovarian Aging, analyzes how stromal cells outside of follicles influence hormone production. This approach focuses on how these non-follicular cells drive mechanisms associated with the biological aging of the ovary.
The players
David Pepin
An associate professor of surgery at Harvard Medical School whose work focuses on ovarian aging and reproductive medicine.
American Society for Reproductive Medicine
A professional organization for reproductive medicine specialists that hosts annual scientific congresses and presents clinical research awards.
The details
Pepin’s research examines the role of ovarian stromal cells—the structural and connective tissue cells within the ovary—in hormone production outside the follicular environment. By mapping how these cells contribute to steroidogenesis, the study suggests that these non-follicular sources are key drivers of ovarian aging. This research aims to define these stromal pathways as potential sites for future therapeutic interventions.
Timeline
The KY Cha Award was established in 2011.
The 82nd Scientific Congress took place in Baltimore from October 24-28, 2026.
The Tech Race
This award marks a significant milestone in ongoing efforts to better understand the mechanisms governing reproductive decline. It positions stromal hormone research alongside broader efforts to mitigate ovarian aging within the global reproductive medicine community.
This research is in the academic stage and does not currently impact clinical fertility treatments or patient care protocols. Patients and providers should monitor future clinical trial publications to see if these findings translate into new diagnostic tools or therapies.
The takeaway
The research establishes a new framework for understanding ovarian aging that could inform future fertility treatments. Observers should track subsequent findings from Pepin's lab regarding the viability of stromal hormone targeting in clinical settings.
Further reading
Explore deeper insights into current research trends by visiting Life Sciences.


